Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2013-10-10 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2013-10-10 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by NeoStem, Inc. It registers additional shares under an equity compensation plan. The text includes details about the registration fee, incorporation by reference of other filings, indemnification provisions, and undertakings related to the registration statement. There are no financial statements or performance data presented. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or other report type. Therefore, it fits the category of Regulatory Filings (RNS).
2013-10-04 English
424B2
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(2) under the Securities Act, related to an offering of 5,000,000 shares of common stock. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company business overview. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. It is a formal filing related to a financing transaction, specifically a public offering of shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence classification as CAP.
2013-10-04 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 3, 2013, reporting an underwritten public offering of common stock by NeoStem, Inc. It details the terms of the offering, the underwriting agreement, use of proceeds, and includes exhibits such as the underwriting agreement and legal opinion. The content focuses on a capital raising event and financing activity. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory filing for certification or attestation only, so not RNS. The document clearly relates to a financing update and capital structure change. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the offering, not just an announcement of a report, so it is not RPA.
2013-10-04 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It includes detailed information about an offering of common stock, underwriting details, risk factors, use of proceeds, and other related information typical of a prospectus supplement. The document references a registration statement and is clearly related to capital raising activities. It is not a full financial report, earnings release, or management discussion, but rather a detailed offering document for securities issuance. Therefore, it fits the category of Capital/Financing Update filings, which cover updates on company fundraising and financing activities.
2013-10-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by NeoStem, Inc. It includes multiple items such as preliminary financial results for the quarter ended September 30, 2013, amendments to the company's equity compensation plan, adoption of an amended and restated certificate of incorporation, election of directors to classified board terms, voting results from the annual meeting, and a press release about an upcoming public offering. The document is not a full annual or quarterly report but a current report disclosing material events and updates. It contains detailed voting results and board changes, which are typical for an 8-K filing. The presence of multiple items including management changes, amendments to corporate documents, and voting results indicates it is a regulatory filing reporting material corporate events rather than a standalone financial report or earnings release. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2013-10-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.